There are 4 phases of a clinical trial, each designed to answer specific questions about a new treatment’s safety and effectiveness. The goal of each phase of a clinical trial is distinct and builds upon the previous phase.

Phase 1: A Phase 1 clinical trial primarily focuses on evaluating the safety of a new treatment, identifying potential side effects, and determining the appropriate dosage in a small group of participants, after undergoing extensive tests in the laboratory. Here, researchers start with low doses and gradually increase them while carefully monitoring participants for adverse reactions. Although Phase 1 trials are not primarily designed to assess effectiveness, any preliminary signs of benefit are noted.

This phase lays the foundation for subsequent trials by establishing the safest and most effective dose to use moving forward.

Phase 2: A Phase 2 clinical trial builds on the safety data from Phase 1 by evaluating whether the treatment is effective, while continuing to monitor for side effects. This phase typically involves a larger group of participants who have the condition the treatment is meant to target.

Researchers use the dose determined in Phase 1 to assess how well the treatment works. Although not yet definitive, Phase 2 trials help determine whether the treatment shows enough promise to move forward into larger, confirmatory studies.

Phase 3: A Phase 3 clinical trial builds on the results from earlier phases by confirming the treatment’s effectiveness in a much larger group of patients. It compares the new treatment to the current standard of care to determine which works better, while continuing to monitor for side effects.

This phase provides the definitive evidence needed to assess the treatment’s overall benefit-risk profile and is often the final step before seeking Federal Food and Drug Administration (FDA) regulatory approval.

Phase 4: This phase takes place after a treatment is approved and widely available, focusing on long-term safety, effectiveness, and outcomes in diverse, real-world populations, sometimes involving thousands of participants. It involves ongoing monitoring which helps identify rare or delayed side effects and ensures continued assessment of the treatment’s overall benefit and risk.

For PTCL patients, clinical trials will typically be in Phase 1 or 2. Phase 3 trials are limited due to the fact that PTCL is a rare condition, and it is difficult to find enough patients to participate. Medications for PTCL have historically been approved from Phase 2 trials.